Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

Completed · Phase 1/Phase 2

Conditions studied: Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Drugs used in chemotherapy, such as fluphenazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I/II trial is studying the side effects and best dose of fluphenazine and to see how well it works in treating patients with refractory advanced multiple myeloma.

Key facts

Study ID

NCT00335647

Run by

Immune Control

People needed

30

Starts

2006-01-01

Last updated by the study team

2013-11-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hackensack University Medical Center Cancer Center — Hackensack, New Jersey, United States
• Long Island Jewish Medical Center — New Hyde Park, New York, United States
• Abramson Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.